A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » IAS 2011

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 20, 2011

HIV Treatment Works in Female Genital Tract

by Tim Horn

Genital secretions from women living with HIV using antiretroviral (ARV) therapy contain high drug concentrations and low amounts of infectious virus, according to an important new study conducted by Anandi Sheth, MD, and her colleagues at the Emory Center for AIDS Research in Atlanta. The results were shared Monday, July 18, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

It is well known that higher concentrations of HIV in genital secretions among women are linked to a greater risk of transmitting the virus to sexual partners, notably in countries where heterosexual sex remains a major risk factor for infection. And while ARVs are known to suppress HIV in the blood and are believed to penetrate the female reproductive tract, studies have documented that HIV can persist in genital secretions, with levels fluctuating during the menstrual cycle.

Research exploring the effects of compounds that target HIV on the female genital tract is essential, given the heightened interest in vaginal microbicides, pre-exposure prophylaxis and treatment as prevention. Determining which approach is most effective in terms of delivering drugs to tissues that are most at risk for HIV or shedding the virus is important.

According to Sheth—whose work reported here qualified her to be the sole recipient of the IAS 2011 Young Investigator Award in prevention science—some ARVs penetrate the female genital tract better than others.

ARVs believed to achieve higher concentrations in the female genital tract than in the blood are: Epivir (lamivudine), Emtriva (emtricitabine), Retrovir (zidovudine), Intelence (etravirine), Crixivan (indinavir), Prezista (darunavir), Selzenty (maraviroc) and Isentress (raltegravir). ARVs less likely to concentrate in the female genital tract, compared with the blood, are: Videx EC (didanosine), Ziagen (abacavir), Zerit (stavudine), Rescriptor (delavirdine), Sustiva (efavirenz), Lexiva (Amprenavir), Norvir (ritonavir), Reyataz (atazanavir), Kaletra (lopinavir) and Invirase (saquinavir). The drugs Viread (tenofovir) and Viramune (nevirapine) have comparable concentrations in blood and the female genital tract.

Sheth and her colleagues set out to characterize female genital tract drug concentrations and HIV shedding over one menstrual cycle among women using a common ARV regimen: Norvir-boosted Reyataz combined with Truvada.
Six pairings of blood and female genital tract samples were collected from 20 women, with two samples collected during the follicular phase (following menstruation but before ovulation) and four collected during the luteal phase (the first day of ovulation through the remainder of the cycle).

The average age of the women was 36, and roughly 95 percent were black. The volunteers knew they were living with HIV for an average of nine years, and most had been on some form of ARV therapy for 90 months and had been on the study regimen for an average of 14 months.

HIV concentrations—both free virus (HIV RNA) and virus already in cells (HIV DNA)—were generally lower in genital secretions than in blood samples, though the assays used in the tests defined “undetectable” differently: Less than 50 for blood and less than 500 for genital secretions. However, even when the result was undetectable, these assays were still able to detect the low-level presence of virus.

HIV RNA was detected in blood samples in 69 of the 120 samples in 16 women (80 percent), whereas HIV RNA was in genital secretion samples in only 19 of 120 samples in 9 women (45 percent). Moreover, 11 of the 120 blood samples, involving 40 percent of the women, had detectable viral loads, whereas there was no detectable virus in any of the genital secretion samples collected from any of the women.

HIV RNA in the blood was more likely to be detectable during the follicular phase and lowest during the beginning of the luteal phase, whereas HIV RNA in the genital tract was more likely to be detected immediately following menstruation and at the beginning of the luteal phase. However, the variability of detectable HIV in genital secretions was not statistically significant, meaning that it could have been due to chance.

The factors shown to be potentially associated with HIV in the genital tract were white blood cells and blood being present in genital secretions.

Interestingly, all active drugs used in the regimen achieved higher concentrations in the female genital tract than in the blood. This finding runs counter to research exploring drug concentrations in the female genital tract, particularly the observation that Reyataz levels in genital secretions exceeded those found in the blood. What’s more, drug levels were consistently higher throughout the menstrual cycles of the 20 women. 

In conclusion, Sheth noted that ARV treatment resulted in adequate female genital tract penetration of all drugs throughout the menstrual cycle. While levels of the emtricitabine and tenofovir in Truvada are similar to those reported previously, the higher levels of Reyataz came as a pleasant surprise.

In the presence of antiretroviral therapy, Sheth reiterated that her group was unable to detect HIV RNA at a quantifiable amount in the female genital tract. And while this is encouraging news, she warned that “detection of low-level genital HIV RNA suggests local viral replication that is not completely inhibited.” She added: “The presence of low-level female genital tract HIV RNA and proviral DNA suggests ARV treatment reduces, but may not completely eliminate, sexual transmission.”

Search: women, genital tract, lavage, fluid, free virus, cell-associated virus, transmission, prevention, treatment, Reyataz, atazanavir, Truvada, tenofovir, emtricitabine, Sheth, IAS, Rome

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.